These findings align with our results, indicating that the JNK/NRF2/HO-1 pathway may act as a critical mediator linking febuxostat-induced XOR inhibition to improved metabolic homeostasis in MASLD. The gene discussed is MAPK8; the disease is metabolic dysfunction-associated steatotic liver disease.